Volume 29, Number 3—March 2023
Research
Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal
Table 1
Sociodemographic and clinical characteristics of COVID-19 case-patients in the study sample, by SARS-CoV-2 variant, Portugal, April 25–June 10, 2022
Characteristic | No. (%) patients |
|||
---|---|---|---|---|
BA.5, n = 12,306 |
BA.2, n = 15,396 |
|||
Sex | ||||
F | 7,176 (58.3) | 9,043 (58.7) | ||
M |
5,130 (41.7) |
6,353 (41.3) |
||
Age group, y | ||||
18–29 | 3,474 (28.2) | 3,299 (21.4) | ||
30–39 | 2,059 (16.7) | 2,922 (19.0) | ||
40–49 | 2,475 (20.1) | 3,431 (22.3) | ||
50–59 | 1,974 (16.0) | 2,581 (16.8) | ||
60–69 | 1,089 (8.9) | 1,567 (10.2) | ||
>70 |
1,235 (10.0) |
1,596 (10.4) |
||
Region | ||||
Alentejo | 1,280 (10.4) | 752 (4.9) | ||
Algarve | 325 (2.6) | 487 (3.2) | ||
Centro | 1,401 (11.4) | 972 (6.3) | ||
Lisboa e Vale do Tejo | 1,462 (11.9) | 3,396 (22.1) | ||
Norte |
7,838 (63.7) |
9,789 (63.6) |
||
Epidemiologic week of diagnosis, 2022 | ||||
Week 17 | 980 (8.0) | 4,200 (27.3) | ||
Week 18 | 3,237 (26.3) | 5,691 (37.0) | ||
Week 19 | 5,655 (46.0) | 4,763 (30.9) | ||
Week 20 | 1,080 (8.8) | 492 (3.2) | ||
Week 21 | 799 (6.5) | 174 (1.1) | ||
Week 22 | 348 (2.8) | 56 (0.4) | ||
Week 23 |
207 (1.7) |
20 (0.1) |
||
COVID-19 vaccination status | ||||
Not vaccinated | 590 (4.8) | 631 (4.1) | ||
Complete primary vaccination | 2,530 (20.6) | 2,434 (15.8) | ||
First booster vaccination |
9,186 (74.7) |
12,331 (80.1) |
||
Previous SARS-CoV-2 infection | ||||
No | 11,073 (90.0) | 14,536 (94.4) | ||
Yes |
1,233 (10.0) |
860 (5.6) |
||
Hospitalization | ||||
No | 12,254 (99.6) | 15,342 (99.7) | ||
Yes | 52 (0.4) |
54 (0.4) |
1These first authors contributed equally to this article.
2These authors contributed equally to this article.